首页> 外文OA文献 >Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

【2h】

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

机译：Eculizumab在AQP4 +神经髓炎OPTICA谱系疾病中的益处：随机控制阶段3的亚组分析防止试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jacqueline Palace; Dean M. Wingerchuk; Kazuo Fujihara; Achim Berthele; Celia Oreja-Guevara; Ho Jin Kim; Ichiro Nakashima; Michael Levy; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Marcus Yountz; Larisa Miller; Róisín Armstrong; Sean Pittock;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial [J] . Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lancet Neurology . 2020,第5期

机译：Satralizumab单药治疗神经髓炎Optica谱系疾病的安全性和有效性：随机，双盲，多期，安慰剂控制第3阶段试验
2. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial [J] . Cree Bruce A. C., Bennett Jeffrey L., Kim Ho Jin, The Lancet . 2019,第10206期

机译：inebilizumab用于治疗神经髓炎光谱紊乱（n-phondum）：双盲，随机安慰剂控制阶段2/3试验
3. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial [J] . Lancet Neurology . 2020,第4期

机译：Rituximab在神经肌炎Optica谱系障碍中的安全性和有效性（rin-1研究）：多期，随机，双盲，安慰剂对照试验
4. Resilience and metacognitions as predictors of outcome in a randomized controlled treatment trial of generalized anxiety disorder [C] . Hjemdal O., Hagen R., Ottesen Kennair Leif E., World Congress on Resilience. . 2014

机译：随机对照治疗试验的预测因子作为综合焦虑症的随机对照治疗试验的预测因素
5. Parent-Child Interaction Therapy for Children with Autism Spectrum Disorder: A Randomized Controlled Trial [D] . Greathouse, Ashley Dawn. 2021

机译：自闭症谱系障碍儿童的亲子儿童互动治疗：随机对照试验
6. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials [O] . Tao Xue, Jiahao Yu, Shujun Chen, 2020

机译：神经肌炎OPTICA谱紊乱中单克隆抗体的不同靶点：从随机对照试验中证明的META分析
7. Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD) [O] . Jeffrey L. Bennett, B. Greenberg, A. Traboulsee, 2019

机译：SATRALIZUAB作为单药治疗塔库拉特预先指定亚疗法的疗效，是神经肌炎OPTICA谱紊乱患者（NMOSD）的双盲安慰剂对照第3期临床研究

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

著录项

引文网络

相似文献

相关主题

期刊订阅